Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, Glomerulonephritis, IGA, Date of authorisation: 15/07/2022, Revision: 5, Status: Authorised
IgAN is caused by the immune system (the body's natural defences) producing a faulty version of immunoglobulin A (IgA), a protein in the blood that identifies and attaches to specific foreign substances. In patients with this condition, faulty IgA builds up in the kidney, damaging them and preventing them from working properly.
The active substance in Kinpeygo, budesonide, is a corticosteroid. Corticosteroids have a wide range of effects that suppress the immune system. In particular, Kinpeygo is designed to release budesonide when it reaches the intestine, where it reduces the production of faulty IgA and thereby reducing IgA build-up and damage to the kidneys.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
